Athera Biotechnologies announces that a composition of matter patent covering antibodies with binding to phosphorylcholine, PC has been allowed by the European Patent Office, EPO.
The PC target is part of modified phospholipids and has been characterized as an active driver of vascular inflammation. The therapeutic antibodies covered by the patent are designed to target and block PC and thereby reduce inflammation.
“The EPO allowance is following the previous grant of corresponding US, Japanese and Australian patents covering both our lead candidate PC-mAb and a second candidate” says Carina Schmidt, CEO of Athera.
The clinical stage fully human antibody PC-mAb from Athera is designed to mimic the anti-inflammatory role of endogenous antibodies against PC and act to support the immune response to vascular inflammation challenges and thereby reduce the risk for complications in immunovascular diseases.
In picture: Knut Pettersson, CSO Carina Schmidt, CEO. Photo: UP THERE, EVERYWHERE AB